RECOVER Study Shows Long COVID Symptoms Eased in 50% of Patients Over Three Years

Symptoms of long COVID eased in 50% of patients within three years of their initial SARS-CoV-2 infection, according to findings from the U.S. RECOVER Adult Study published in the Annals of Internal Medicine and reported by livescience.com livescience.comlivescience.comlivescience.comOpen source ↗. Funded by the National Institutes of Health, the prospective study tracked nearly 1,020 adult patients across the United States who scored more than 10 points on the 30-point 2024 LC Research Index (LCRI). Participants completed in-person evaluations and questionnaires every three months to monitor issues including fatigue, cognitive impairment, shortness of breath, and palpitations livescience.comlivescience.comlivescience.comOpen source ↗.

Investigators defined clinical improvement as reaching an LCRI score of 10 or lower across two consecutive visits. The data showed that 36% of participants reached this threshold two years after infection, increasing to 50% at the three-year mark livescience.comlivescience.comlivescience.comOpen source ↗. Additionally, 26% of patients recorded an LCRI score of zero at three years, signaling that all tracked symptoms had resolved at the time of assessment livescience.comlivescience.comlivescience.comOpen source ↗. Co-author Harrison Reeder of Massachusetts General Hospital noted that researchers avoided the term "recovered" because symptoms can fluctuate, and the protocol did not assess whether improved patients later experienced relapses.

Subtype Disparities

Patient trajectories varied sharply based on underlying symptom profiles. Roughly 60% of individuals whose primary symptoms involved loss of taste or smell improved within three years. Conversely, fewer than 20% of participants with multisystem symptoms—specifically 19% in the most complex presentation involving cardiac, nervous, and gastrointestinal manifestations—showed improvement over the same period livescience.comlivescience.comlivescience.comOpen source ↗.

Clinical Trial Implications

Age and viral lineage also influenced long-term outcomes. Participants under 46 years old and those infected with Omicron variants were more likely to show improvement than older adults or those infected with earlier viral strains livescience.comlivescience.comlivescience.comOpen source ↗. Commenting on the findings, Dr. Carmen Scheibenbogen of Charité University Medicine Berlin observed that the multisystem cohort closely resembles patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Both Scheibenbogen and Reeder emphasized that future clinical trials evaluating targeted therapies must account for these distinct clinical subtypes livescience.comlivescience.comlivescience.comOpen source ↗.